ASCO GU 2024 Prostate Cancer - Results from #80

Viewing 81-95 of 95 articles

ASCO GU 2024: Mature Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

ASCO GU 2024: Interaction of Age and Benefit of Treatment Intensification in Advanced Prostate Cancer: An Aggregate Meta-Analysis of 14 Randomized Trials

ASCO GU 2024: Exploratory Analyses of Homologous Recombination Repair Gene Subgroups and Potential Associations with Secondary Efficacy Endpoints in the HRR-Deficient Population from TALAPRO-2

ASCO GU 2024: Evaluating Early Changes in Circulating Tumor DNA Tumor Fraction as a Value Add to PSA in Predicting Early Progression in mCRPC

ASCO GU 2024: Efficacy of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Single Homologous Recombination Repair Gene Mutations in the PROpel Trial

ASCO GU 2024: CYPIDES Phase 2 Results MK-5684 (ODM-208), a CYP11A1 Inhibitor, in Patients with mCRPC with and without AR-LBD Mutations

ASCO GU 2024: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel: A Sensitivity Analysis from ARASENS Accounting for Subsequent Therapy

ASCO GU 2024: Radiographic Progression Without PSA Progression in Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis from the ENZAMET Trial (ANZUP 1304)

ASCO GU 2024: Enzalutamide Combination Treatment Suspension in Men with High-Risk Biochemically Recurrent Prostate Cancer: Outcomes from EMBARK

ASCO GU 2024: Underutilization of ADT Intensification for the Treatment of Men with mHSPC: A Systematic Review of Real-World Database Studies

ASCO GU 2024: Safety Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223 Following External Beam Radiation Therapy: REASSURE US Subset

ASCO GU 2024: Post Hoc Analysis of rPFS and OS from the TALAPRO-2 (TP-2) Study: Genomic Subgroups Based on Likelihood of BRCA or HRR Gene Alteration Status

ASCO GU 2024: Enfortumab Vedotin as Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results of Stage I of a Phase 2 Trial

ASCO GU 2024: Phase 1 Results and Phase 2 Design - Oral Epi-7386 (Masofaniten) in Combination With Enzalutamide Compared to Enzalutamide Alone in Patients with mCRPC

ASCO GU 2024: Intensification of ADT with Enzalutamide in High-Risk Patients with Biochemical Relapse Following Radical Prostatectomy Undergoing Salvage Radiation: Initial Results from RTOG 3506 (STEEL)

1
2
3
4
5